|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | DC-CIK联合化疗治疗非小细胞肺癌的临床疗效评价(英文)显示文摘Objective: The aim of the study was to evaluate the safety and therapeutic effects of autologous dendritic cells co-cultured with cytokine-induced killer cells (DC-CIK) combined with chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. Methods: Fifty patients with advanced NSCLC (stages III to IV), who had received therapies in our Center (Department of Biotherapy, Affiliated to Cancer Hospital of Shanxi Medical University, Taiyuan, China) from August 2008 to January 2010, were treated by DC-CIK + chemotherapy as the combined treatment group; fifty advanced NSCLC patients treated with chemotherapy at the same time served as controls. The immunologic function, short-term therapeutic effects, the 1-year survival rate, the life quality, the chemotherapy side effects were compared between the two groups, the safety and therapeutic effects of DC-CIK cells therapy were observed too. Results: There was no obvious change of subsets of T cells in peripheral blood before and after therapy in DC-CIK + chemotherapy group, and IFN-γ was improved after therapy in this group (P < 0.05); in chemotherapy alone group, the ratios of CD3+CD4+, CD3+CD8+, CD3-CD56+ cells and the secretion of IL-2, TNF-α decreased significantly after therapy (P < 0.05); the ratios of CD3+CD8+, CD3+CD56+ were improved after cell culture (P < 0.05). The disease control rate (DCR) of DC-CIK + chemotherapy group was higher than that in the chemotherapy alone group (78.0% vs 56.0%, P < 0.05); the 1-year survival rates of DC-CIK + chemotherapy group and chemotherapy alone group were 50% and 44% respectively, had no significant difference. Compared with chemotherapy alone group, the occurrence of chemotherapy side effects (including bone marrow suppression, nausea and vomiting, peripheral nerve toxicity) was less in the DC-CIK + chemotherapy group (P < 0.05). The physical and appetite were better in DC-CIK + chemotherapy group after therapy. Conclusion: To compare with simple chemotherapy, DC-CIK + chemotherapy for advanced NSCLC is safe and effective, and it can improve patients' life quality and remission rate, and prolong their survival time. | Junping Zhang Guanghua Mao Yaping Han Xiaoling Yang Huijing Feng Linzi Jia Ting Zhi Yan Xiao Libin Zhang Jiangtao Wang Tianliang Shi | 2012 | The Chinese-German Journal of Clinical Oncology2012，11，2： | 3 |
| 2 | Dietary ad-ministration of berberine or PheUodendron amurense ex-tract inhibits cell cycle progression and lung tumorigen-esis显示文摘 | James Michael A Fu Huijing Liu Yan | 2011 | Molecular Carcinogenesis2011，50，1： | 1 |
| 3 | Adhesion hysteresis of a film-terminated fibrillar array显示文摘Motivated by the recent biomimic design of microstructured adhesive surfaces,we study adhesion between a film-terminated fibrillar array and a rigid substrate.Using a two-dimensional model and ignoring the deformation of the fibers and the backing layer,we show that the adhesion behavior is dominated by a dimensionless parameter reflecting the global flexibility of the terminal film.In particular,if the parameter is larger than 0.4,the adhesion is reversible;otherwise one or more hysteresis loops will appear after an approach-retraction cycle,leading to significant increase in the specific separation work.The result is expected to help not only optimal design of the structure,but also other applications such as micro-manipulation in micromechanical systems. | YAN ShunPing HE LingHui WANG HuiJing | 2012 | Science China(Physics,Mechanics & Astronomy)2012，55，6： | 1 |
| 4 | Full-profile pharmacokinetics, anticancer activity and toxicity of an extended release trivalent PEGylated irinotecan prodrug显示文摘Irinotecan is an anticancer topoisomerase I inhibitor that acts as a prodrug of the active metabolite,SN-38.Unfortunately,the limited utility of irinotecan is attributed to its pH-dependent stability,short half-life and dose-limiting toxicity.To address this problem,a novel trivalent PEGylated prodrug(PEG-[Irinotecan]3)has been synthesized and its full-profile pharmacokinetics,antitumor activity and toxicity compared with those of irinotecan.The results show that after intravenous administration to rats,PEG-[Irinotecan]3 undergoes stepwise loss of irinotecan to form PEG-[Irinotecan]3-x(x=1,2)and PEG-[linker]during which time the released irinotecan undergoes conversion to SN-38.As compared with conventional irinotecan,PEG-[Irinotecan]3 displays extended release of irinotecan and efficient formation of SN-38 with significantly improved AUC and half-life.In a colorectal cancer-bearing model in nude mice,the tumor concentrations of irinotecan and SN-38 produced by PEG-[Irinotecan]3 were respectively 86.2 and 2293 times higher at 48 h than produced by irinotecan.In summary,PEG-[Irinotecan]3 displays superior pharmacokinetic characteristics and antitumor activity with lower toxicity than irinotecan.This supports the view that PEG-[Irinotecan]3 is a superior anticancer drug to irinotecan and it has entered the phaseⅡtrial stage. | Shiwen Song Dong Sun Hong Wang Jinliang Wang Huijing Yan Xuan Zhao John Paul Fawcett Xin Xu Deqi Cai Jingkai Gu | 2023 | Acta Pharmaceutica Sinica B2023，13，8： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员